Cavernous sinus meningioma

Summary

Cavernous sinus meningioma (MONDO:0002996) is a disease and 3 clinical trials. A subtype of skull base meningioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cavernous sinus meningioma
Mondo ID	MONDO:0002996
DOID	DOID:4435
NCIT	C5268
UMLS	C1332865
MedGen	232034
GARD	0023317
Anatomy (UBERON)	UBERON:0003712
Is cancer (heuristic)	no

Also known as: cavernous sinus meningioma (disease) · meningioma (disease) of cavernous sinus · meningioma of cavernous sinus · meningioma of the cavernous sinus

Disease family

This is a subtype of skull base meningioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › head and neck neoplasm › skull neoplasm › skull base neoplasm › skull base meningioma › cavernous sinus meningioma

Related subtypes (9): foramen magnum meningioma, clivus meningioma, multiple skull base meningioma, diaphragma sellae meningioma, suprasellar meningioma, petroclival meningioma, sphenoorbital meningioma, sphenocavernous meningioma, pituitary stalk meningioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05895344	Not specified	RECRUITING	Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: An Open-label Randomized 1:1 Phase III Study
NCT02750371	Not specified	COMPLETED	Effect of Irradiation of the Cavernous Sinus and the Sellar Region on Autobiographical Memory
NCT06721130	Not specified	COMPLETED	Role of 18F-FDG PET/CT in the Evaluation of Cavernous Sinus Syndrome: a Pilot Study